According to Insulet's latest financial reports the company has a price-to-book ratio of 22.4.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 42.9 | 30.1% |
2021-12-31 | 33.0 | 18.14% |
2020-12-31 | 27.9 | -80.25% |
2019-12-31 | 141 | 538.77% |
2018-12-31 | 22.1 | -12.61% |
2017-12-31 | 25.3 | -26.08% |
2016-12-31 | 34.3 | -45.82% |
2015-12-31 | 63.2 | 104.45% |
2014-12-31 | 30.9 | 89.33% |
2013-12-31 | 16.3 | -29.67% |
2012-12-31 | 23.2 | 85.84% |
2011-12-31 | 12.5 | 17.54% |
2010-12-31 | 10.6 | 4.26% |
2009-12-31 | 10.2 | -77.97% |
2008-12-31 | 46.3 | 609.85% |
2007-12-31 | 6.52 | |
2006-12-31 | N/A | |
2005-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 5.25 | -76.51% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 4.83 | -78.40% | ๐บ๐ธ USA |
![]() Medtronic MDT | 2.05 | -90.84% | ๐ฎ๐ช Ireland |
![]() Eli Lilly LLY | 49.4 | 120.87% | ๐บ๐ธ USA |
![]() Tandem Diabetes Care
TNDM | 4.99 | -77.70% | ๐บ๐ธ USA |
![]() ICU Medical
ICUI | 1.01 | -95.50% | ๐บ๐ธ USA |
![]() DexCom DXCM | 5.10 | -77.21% | ๐บ๐ธ USA |